Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FAVQX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,557
Award facts
- Contract value 100% obligated
- $26,557.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $26,557.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Dupixent 300 mg/2 mL pen injections. The award was issued on June 25, 2025, with an ultimate completion date of June 26, 2025, under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to a location in Conshohocken, Pennsylvania. This delivery order falls under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and extending through November 2026, which establishes a comprehensive pharmaceutical supply framework for military health facilities.
DMS Pharmaceutical Group, headquartered in Park Ridge, Illinois, has maintained an active federal contracting presence since 2001 and specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare systems nationwide. The company's extensive portfolio with the Defense Logistics Agency demonstrates its established role as a critical supplier within the federal pharmaceutical supply chain, delivering specialty medications and injectable products to support military medical facilities. Dupixent, a biologic medication used for treating eczema and asthma, represents the type of specialized pharmaceutical product the company routinely supplies through its indefinite delivery contract vehicle.
Quick answers
Who was awarded contract SPE2DB25FAVQX?
SPE2DB25FAVQX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 25, 2025.
How much is contract SPE2DB25FAVQX worth?
The government has obligated $26,557 on SPE2DB25FAVQX.
Is contract SPE2DB25FAVQX an order under another contract?
Yes. SPE2DB25FAVQX is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB25FAVQX competed?
The extent of competition for SPE2DB25FAVQX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award